| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
MAPK/mitogen-activated protein kinase kinase
|
|---|---|
| References | |
| Additional Infomation |
Specificity analyses targeting 70-80 protein kinases have been performed on 65 compounds that have been reported as relatively specific protein kinase inhibitors. Based on this information, the cellular effects of the compounds we studied, and other data in the literature, we recommend the following small molecule inhibitors: SB 203580/SB202190 and BIRB 0796 used in parallel to evaluate the physiological effects of the p38 MAPK (mitogen-activated protein kinase) isoform; PI-103 and wortmannin used in parallel to inhibit phosphatidylinositol 3-kinase; PP1 or PP2 used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 for inhibiting MKK1 (MAPK kinase-1) or MKK1 plus MKK5; Akt-I-1/2 for inhibiting PKB (protein kinase B/Akt) activation; rapamycin for inhibiting TORC1 [mTOR (target of rapamycin)-raptor (mTOR-regulated protein) complex]; and CT 99021. For inhibiting GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethyl ketone) were used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 was used to inhibit CK1 (casein kinase 1), VX680 was used to inhibit Aurora kinase, and roscovitine was used as a pan-CDK (cyclin-dependent kinase) inhibitor. We also found that halamine is a potent and specific in vitro inhibitor of DYRK1A (bispecific tyrosine phosphorylation and regulation kinase 1A). These results further highlight the need for extreme caution when using small molecule protein kinase inhibitors to assess the physiological functions of these enzymes. Despite the wide applicability of these compounds, many of the compounds we analyzed were too low in specificity to draw any useful conclusions other than excluding specific protein kinases involved in cellular processes. [1]
|
| Molecular Formula |
C8H5N2O4F3S
|
|---|---|
| Molecular Weight |
498.65
|
| Exact Mass |
497.965
|
| CAS # |
1003216-77-0
|
| PubChem CID |
25163987
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.628
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
26
|
| Complexity |
468
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
IC1=CC(Cl)=C(NC2=C(C(NOC[C@H](O)CO)=O)C=CC(F)=C2F)C=C1
|
| InChi Key |
FCADPEDUULETPK-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C16H14ClF2IN2O4/c17-11-5-8(20)1-4-13(11)21-15-10(2-3-12(18)14(15)19)16(25)22-26-7-9(24)6-23/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
|
| Chemical Name |
2-(2-chloro-4-iodoanilino)-N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluorobenzamide
|
| Synonyms |
(R)-PD 0325901CL; 1003216-77-0; PD 0325901-Cl (R form); 2-[(2-Chloro-4-Iodophenyl)amino]-N-{[(2r)-2,3-Dihydroxypropyl]oxy}-3,4-Difluorobenzamide; CHEMBL573819; SCHEMBL21067871;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0054 mL | 10.0271 mL | 20.0541 mL | |
| 5 mM | 0.4011 mL | 2.0054 mL | 4.0108 mL | |
| 10 mM | 0.2005 mL | 1.0027 mL | 2.0054 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
